Pfizer Inc. (NYSE:PFE)

The provision for taxes on income demonstrates significant fluctuations over the five-year period. Current tax expense generally increased from 2021 to 2022, then decreased substantially in subsequent years. Deferred tax benefits consistently offset a portion of the current tax expense, and also exhibited a decreasing trend in absolute value, though remaining negative throughout the period.

Current Tax Expense

Current tax expense increased from US$6,145 million in 2021 to US$7,092 million in 2022, representing a growth of approximately 15.5%. Following this increase, a marked decline is observed, with expense falling to US$2,328 million in 2023, US$2,074 million in 2024, and US$1,866 million in 2025. This represents a cumulative decrease of approximately 73.5% from the 2022 peak.

Deferred Tax Benefit

Deferred tax benefits were substantial in each year, consistently reducing the overall tax provision. The benefit decreased in magnitude from US$-4,293 million in 2021 to US$-3,764 million in 2022, US$-3,443 million in 2023, US$-2,102 million in 2024, and US$-2,133 million in 2025. While consistently negative, the rate of decrease slowed between 2023 and 2025.

Provision (Benefit) for Taxes on Income

The net provision for taxes on income reflects the combined effect of current tax expense and deferred tax benefits. A positive value indicates a tax expense, while a negative value indicates a tax benefit. The provision was positive in 2021 and 2022, at US$1,852 million and US$3,328 million respectively. In 2023, the provision shifted to a benefit of US$-1,115 million. This benefit expanded in 2024 to US$-28 million, before becoming a larger benefit of US$-267 million in 2025. The shift from a provision to a benefit suggests changes in taxable income, tax rates, or the utilization of tax loss carryforwards or other tax credits.

The substantial decrease in current tax expense, coupled with the diminishing deferred tax benefits, resulted in a significant swing from a tax provision to a tax benefit over the observed period. Further investigation would be required to determine the underlying drivers of these changes, such as changes in profitability, geographic earnings mix, or tax planning strategies.

The effective income tax rate exhibits significant fluctuations over the observed period. While the U.S. federal statutory income tax rate remained constant at 21.00% throughout the years, the effective tax rate demonstrates considerable variance, indicating factors beyond the standard corporate rate are influencing the company’s tax obligations.

Effective Tax Rate Trend

In 2021, the effective tax rate was 7.60%. This increased to 9.60% in 2022, suggesting a shift in the composition of income or the utilization of tax benefits. However, a dramatic decrease occurred in 2023, with the effective tax rate becoming negative at -105.40%. This substantial decline implies the realization of significant tax benefits, potentially related to one-time events or changes in tax law, exceeding taxable income. The rate partially recovered to -0.40% in 2024, still indicating a net tax benefit, but to a lesser extent. Finally, in 2025, the effective tax rate moved to -3.50%, continuing to show a net tax benefit, though less pronounced than in 2023.

The large negative effective tax rates in 2023, 2024, and 2025 warrant further investigation. These rates suggest the company benefited from tax credits, deductions, or other adjustments that substantially reduced its tax liability. The magnitude of the 2023 figure, in particular, suggests a potentially unusual or non-recurring item impacted the tax expense. A detailed review of the company’s tax footnotes would be necessary to understand the specific drivers behind these fluctuations.

Discrepancy between Statutory and Effective Rates

The consistent difference between the U.S. federal statutory income tax rate and the effective tax rate highlights the impact of various factors, including international operations, tax credits, and permanent differences in income recognition. The substantial deviations observed, especially the negative rates, indicate these factors are having a material effect on the company’s overall tax position.

Continued monitoring of the effective tax rate is recommended, along with a thorough understanding of the underlying components contributing to its variability. This will provide valuable insights into the company’s tax planning strategies and potential exposures.

The composition of deferred tax assets and liabilities exhibits significant fluctuations over the five-year period. Gross deferred tax assets increased substantially from 2021 to 2023, peaking at US$19,037 million, before stabilizing and experiencing a slight decline in 2025. Simultaneously, deferred tax liabilities also increased considerably, though at a faster rate, reaching US$16,171 million in 2023 before decreasing in the subsequent years. The net effect resulted in a net deferred tax asset, which grew from US$1,269 million in 2021 to a high of US$5,033 million in 2025.

Key Drivers of Deferred Tax Assets

Research and development expenses consistently represent the largest component of gross deferred tax assets, increasing dramatically from US$1,656 million in 2021 to US$7,635 million in 2024, and remaining high at US$7,235 million in 2025. Net operating loss/tax credit carryforwards also contribute significantly, growing from US$1,431 million to US$2,708 million between 2021 and 2023, then decreasing to US$1,763 million in 2025. Prepaid/deferred items also show an overall increasing trend, rising from US$1,889 million in 2021 to US$3,516 million in 2025. Employee benefits represent a substantial portion, decreasing from US$1,594 million in 2021 to US$842 million in 2025.

Key Drivers of Deferred Tax Liabilities

Intangible assets consistently constitute the largest portion of deferred tax liabilities, increasing significantly from US$4,577 million in 2021 to US$11,605 million in 2023, and then decreasing to US$8,810 million in 2025. Property, plant, and equipment also contribute substantially, increasing from US$1,647 million in 2021 to US$2,039 million in 2023, and then decreasing to US$1,771 million in 2025. Investments also contribute to deferred tax liabilities, with fluctuations throughout the period. Unremitted earnings consistently represent a smaller, but growing, portion of the total.

Valuation Allowance

A valuation allowance against deferred tax assets is maintained throughout the period, ranging from US$1,463 million in 2021 to US$1,738 million in 2023, and decreasing to US$1,546 million in 2025. The consistent presence of a valuation allowance suggests some uncertainty regarding the realization of a portion of the deferred tax assets.

The significant increase in both gross deferred tax assets and liabilities, particularly driven by research and development and intangible assets respectively, suggests substantial activity related to these items. The net deferred tax asset position indicates that the company anticipates future taxable income sufficient to utilize its deferred tax assets, although the valuation allowance suggests some degree of caution regarding full realization. The fluctuations in specific components require further investigation to understand the underlying business transactions and tax planning strategies driving these changes.

The values associated with noncurrent deferred tax assets and liabilities demonstrate significant fluctuations over the five-year period. A notable increase in both assets and liabilities is observed between 2021 and 2022, followed by shifts in subsequent years.

Noncurrent Deferred Tax Assets

Noncurrent deferred tax assets began at US$1,618 million in 2021 and increased substantially to US$4,769 million in 2022. A considerable decrease followed in 2023, with the value falling to US$1,768 million. Further increases were then recorded in 2024 and 2025, reaching US$6,573 million and US$7,434 million respectively. This indicates a volatile pattern, with large swings in the anticipated future tax benefits recognized as assets.

Noncurrent Deferred Tax Liabilities

Noncurrent deferred tax liabilities exhibited a similar pattern of growth between 2021 and 2022, rising from US$349 million to US$1,023 million. The value decreased to US$640 million in 2023, before increasing again to US$2,122 million in 2024 and US$2,401 million in 2025. The increases in liabilities suggest growing obligations for future tax payments based on temporary differences.

Net Deferred Tax Position

The difference between noncurrent deferred tax assets and liabilities reveals a net asset position throughout the period. However, the magnitude of this net asset position fluctuates considerably. In 2021, the net asset was US$1,269 million (US$1,618 - US$349). This increased to US$3,746 million in 2022, decreased to US$1,128 million in 2023, and then rose to US$4,451 million in 2024 and US$5,033 million in 2025. These changes suggest a dynamic interplay between the recognition of future deductible temporary differences (assets) and taxable temporary differences (liabilities).

The substantial changes in both deferred tax asset and liability balances warrant further investigation to understand the underlying causes. These fluctuations could be driven by changes in tax laws, accounting policy adjustments, or significant shifts in the company’s business operations and related temporary differences.

The financial information reveals adjustments made to reported figures, primarily relating to the removal of deferred tax assets and liabilities. These adjustments consistently reduce reported asset, liability, and shareholders’ equity values across the observed period, impacting reported net income as well.

Total Assets & Liabilities

Reported total assets increased from 2021 to 2023, peaking at US$226,501 million, before declining in 2024 and 2025. The adjusted total assets follow a similar pattern, consistently lower than the reported values. The difference between reported and adjusted total assets ranged from approximately US$1.6 billion in 2021 to US$6.5 billion in 2023, suggesting a significant deferred tax impact on asset valuation. Reported total liabilities exhibited a decrease in 2022, followed by a substantial increase through 2023, and subsequent declines in 2024 and 2025. Adjusted total liabilities mirrored this trend, remaining consistently below reported liabilities.

Shareholders’ Equity

Reported total shareholders’ equity increased significantly from 2021 to 2022, then decreased in subsequent years. The adjusted shareholders’ equity values are consistently lower, with a similar trend. The gap between reported and adjusted equity values remained relatively stable, ranging from approximately US$1.3 billion to US$2.4 billion throughout the period, indicating a consistent impact from deferred tax adjustments on equity.

Net Income

Reported net income attributable to common shareholders peaked in 2022 at US$31,372 million, followed by a substantial decline in 2023 and a partial recovery in 2024 and 2025. The adjusted net income demonstrates a similar pattern, but with lower values overall. Notably, the adjusted net income was negative in 2023 (-US$1,324 million), while the reported net income was positive (US$2,119 million). This divergence highlights the significant impact of removing deferred tax benefits on the reported profitability. The difference between reported and adjusted net income widened considerably in 2023, suggesting a substantial deferred tax expense was removed from the adjusted figures.

Overall, the adjustments consistently reduce reported financial statement values. The most substantial impact is observed on net income, particularly in 2023, where the removal of deferred tax benefits resulted in a shift from reported profitability to adjusted losses. The consistent reduction in assets, liabilities, and equity suggests a systematic approach to removing deferred tax items from the financial statements.

The financial performance metrics exhibit notable differences between reported and adjusted values following the removal of deferred tax impacts. Generally, the adjustments result in lower profitability ratios and, in one instance, a negative return. Asset turnover remains largely unaffected, while leverage ratios experience minor increases with the adjustments. The period between 2021 and 2023 demonstrates the most significant shifts, with a stabilization of adjusted figures from 2024 to 2025.

Profitability

Reported net profit margin increased from 26.76% in 2021 to 31.01% in 2022 before a substantial decline to 3.56% in 2023, followed by a recovery to 12.62% and 12.42% in 2024 and 2025, respectively. The adjusted net profit margin follows a similar trend, increasing from 21.53% to 27.29% then decreasing to -2.22% in 2023, and recovering to 9.32% and 9.01% in 2024 and 2025. The adjustments consistently lower the reported margins, and result in a negative margin in 2023, indicating a significant impact from deferred tax considerations during that year. The difference between reported and adjusted values suggests deferred taxes were contributing positively to reported profits in 2021 and 2022, but negatively in 2023, 2024 and 2025.

Asset Utilization

Reported total asset turnover decreased from 0.45 in 2021 to 0.26 in 2023, with a slight increase to 0.30 in both 2024 and 2025. The adjusted total asset turnover mirrors this pattern closely, showing minimal variation from the reported figures. This indicates that the removal of deferred tax assets or liabilities has a negligible effect on how efficiently assets are used to generate revenue.

Financial Leverage

Reported financial leverage fluctuated between 2.06 and 2.54 over the period. The adjusted financial leverage ratios are consistently slightly higher than the reported values, increasing from 2.37 in 2021 to 2.46 in 2025. This suggests that the adjustments related to deferred taxes slightly increase the company’s reliance on debt financing when considering the adjusted figures.

Returns

Reported ROE decreased significantly from 28.47% in 2021 to 2.38% in 2023, before recovering to 9.11% and 8.99% in 2024 and 2025. The adjusted ROE exhibits a similar pattern, declining to -1.51% in 2023 and recovering to 7.08% and 6.92% in 2024 and 2025. The adjusted ROE is consistently lower than the reported ROE, and becomes negative in 2023, mirroring the trend observed in net profit margin. Reported ROA followed a similar pattern, decreasing from 12.11% in 2021 to 0.94% in 2023, and recovering to 3.76% and 3.73% in 2024 and 2025. The adjusted ROA also decreased to -0.59% in 2023, and recovered to 2.87% and 2.81% in 2024 and 2025. The adjustments consistently lower the reported ROA, and result in a negative return in 2023.

In summary, the removal of deferred tax effects significantly impacts profitability metrics, particularly in 2023, resulting in lower returns on equity and assets. Asset utilization and financial leverage are less affected by these adjustments. The stabilization of adjusted figures from 2024 to 2025 suggests a more consistent underlying performance once the impact of deferred taxes is accounted for.

The period under review demonstrates significant fluctuations in reported and adjusted net income, consequently impacting associated profit margins. A notable divergence exists between the reported and adjusted net profit margins, suggesting the influence of specific adjustments to net income.

Reported Net Profit Margin

The reported net profit margin exhibited an initial increase from 26.76% in 2021 to a peak of 31.01% in 2022. Following this, a substantial decline occurred, with the margin falling to 3.56% in 2023. A partial recovery was observed in 2024 and 2025, reaching 12.62% and 12.42% respectively, indicating a stabilization but remaining significantly below the 2022 high.

Adjusted Net Profit Margin

The adjusted net profit margin mirrored the general trend of the reported margin through 2022, increasing from 21.53% to 27.29%. However, the adjusted margin experienced a more dramatic shift in 2023, resulting in a negative value of -2.22%. This indicates substantial adjustments negatively impacting net income. Subsequent years showed improvement, reaching 9.32% in 2024 and 9.01% in 2025, but remained considerably lower than prior levels.

Relationship between Reported and Adjusted Margins

The difference between the reported and adjusted net profit margins widened considerably in 2023, and remained elevated in 2024 and 2025. This suggests that the adjustments made to arrive at the adjusted net income figure were particularly significant during these periods. The negative adjusted net profit margin in 2023 highlights the substantial impact of these adjustments, potentially related to one-time events or accounting changes.

Overall Trend

From 2021 to 2025, both reported and adjusted net profit margins experienced a period of growth followed by a significant downturn in 2023. While a degree of recovery is evident in 2024 and 2025, the margins have not returned to their earlier levels. The consistent difference between the reported and adjusted figures warrants further investigation into the nature of the adjustments being made.

An examination of the provided financial information reveals trends in total assets and associated turnover ratios over a five-year period. Reported total assets generally increased from 2021 to 2023, before declining in both 2024 and 2025. Adjusted total assets mirrored this pattern, exhibiting similar increases and subsequent decreases. The adjusted total asset turnover ratio demonstrates a relatively stable, albeit low, performance in recent years.

Total Assets

Reported total assets increased from US$181.476 billion in 2021 to US$226.501 billion in 2023, representing a substantial growth period. However, a subsequent decline was observed, with assets decreasing to US$213.396 billion in 2024 and further to US$208.160 billion in 2025. Adjusted total assets followed a similar trajectory, starting at US$179.858 billion in 2021, peaking at US$224.733 billion in 2023, and then decreasing to US$206.823 billion and US$200.726 billion in 2024 and 2025 respectively.

Asset Turnover Ratios

Both the reported and adjusted total asset turnover ratios initially increased from 2021 to 2022. The reported ratio rose from 0.45 to 0.51, while the adjusted ratio increased from 0.46 to 0.53. A significant decrease in both ratios occurred in 2023, with both falling to 0.26. These ratios remained relatively stable at 0.30 and 0.31 respectively for 2024 and 2025. The adjusted total asset turnover ratio consistently remained slightly higher than the reported ratio throughout the period.

The decline in asset turnover ratios beginning in 2023, despite the continued high level of assets, suggests a potential decrease in the efficiency with which assets are being utilized to generate revenue. The stabilization of these ratios in the final two years of the period indicates that this decreased efficiency has persisted. The difference between reported and adjusted total asset turnover is minimal, suggesting that the adjustments made to total assets do not significantly impact the turnover calculation.

An examination of the financial information reveals trends in both reported and adjusted financial leverage over a five-year period. Both total assets and shareholders’ equity experienced fluctuations during this time, impacting the calculated leverage ratios. The adjusted figures, while closely mirroring the reported values, present a slightly different perspective on the company’s financial structure.

Total Assets

Reported total assets increased from US$181,476 million in 2021 to US$226,501 million in 2023, representing substantial growth. However, assets then decreased in both 2024 and 2025, falling to US$208,160 million. Adjusted total assets followed a similar pattern, with growth through 2023 and subsequent declines. The difference between reported and adjusted assets remains relatively consistent across all years, suggesting a systematic adjustment is being applied.

Shareholders’ Equity

Reported total shareholders’ equity increased significantly from US$77,201 million in 2021 to US$95,661 million in 2022. A decrease was then observed in 2023 and continued through 2025, reaching US$86,476 million. Adjusted shareholders’ equity mirrors this trend, though the absolute values are consistently lower. The consistent difference between reported and adjusted equity suggests a recurring adjustment impacting this figure.

Financial Leverage

Reported financial leverage decreased from 2.35 in 2021 to 2.06 in 2022, indicating a reduced reliance on debt financing relative to equity. Leverage then increased to 2.54 in 2023 before decreasing slightly to 2.42 in 2024 and remaining stable at 2.41 in 2025. Adjusted financial leverage exhibits a nearly identical pattern, fluctuating between 2.37 and 2.46 over the period. The close alignment between reported and adjusted leverage suggests the adjustments to assets and equity have a limited impact on the overall leverage ratio.

Overall, the company demonstrated growth in asset base and equity through 2023, followed by a contraction in both metrics in the subsequent two years. Despite these fluctuations, the financial leverage remained relatively stable, indicating a consistent capital structure. The adjustments made to both total assets and shareholders’ equity do not materially alter the observed leverage trends.

The period between 2021 and 2025 demonstrates significant fluctuations in reported and adjusted net income, impacting return on equity calculations. Reported net income attributable to Pfizer Inc. common shareholders peaked in 2022 at US$31,372 million before experiencing a substantial decline to US$2,119 million in 2023, followed by a partial recovery to US$8,031 million in 2024 and remaining relatively stable at US$7,771 million in 2025. A similar pattern is observed in adjusted net income, though the magnitude of the decline in 2023 is more pronounced, resulting in a negative value of US$-1,324 million. Total shareholders’ equity, both reported and adjusted, generally increased from 2021 to 2023, then decreased through 2025.

Reported Return on Equity (ROE)

Reported ROE mirrored the trend in reported net income. It rose from 28.47% in 2021 to a high of 32.79% in 2022, then sharply decreased to 2.38% in 2023. A recovery occurred in 2024 and 2025, reaching 9.11% and 8.99% respectively, but remained significantly below the 2021 and 2022 levels.

Adjusted Return on Equity (ROE)

Adjusted ROE followed a similar trajectory to reported ROE, but with more pronounced fluctuations. It began at 23.29% in 2021, increased to 30.04% in 2022, and then experienced a substantial decline, resulting in a negative value of -1.51% in 2023. Adjusted ROE recovered to 7.08% in 2024 and 6.92% in 2025, but remained considerably lower than the values observed in the earlier years of the period.

The divergence between reported and adjusted ROE suggests the presence of significant non-recurring items or accounting adjustments impacting net income. The negative adjusted ROE in 2023 indicates that, excluding these adjustments, the company experienced a loss in that year. The consistent decrease in both reported and adjusted shareholders’ equity from 2023 to 2025, despite positive net income in 2024 and 2025, warrants further investigation to understand the underlying drivers, such as potential share repurchases or dividend payouts.

Shareholders’ Equity Trends

Reported total shareholders’ equity increased from US$77,201 million in 2021 to US$95,661 million in 2022, then decreased to US$89,014 million in 2023, and continued to decline to US$88,203 million in 2024 and US$86,476 million in 2025. Adjusted total shareholders’ equity exhibited a similar pattern, moving from US$75,932 million in 2021 to US$91,915 million in 2022, then decreasing to US$87,886 million in 2023, US$83,752 million in 2024, and US$81,443 million in 2025.

The period between 2021 and 2025 demonstrates significant fluctuations in reported and adjusted net income, impacting return on assets calculations. Reported net income attributable to Pfizer Inc. common shareholders peaked in 2022 at US$31,372 million before experiencing a substantial decline to US$2,119 million in 2023, followed by a partial recovery to US$8,031 million in 2024 and remaining relatively stable at US$7,771 million in 2025. Adjusted net income mirrors this trend, though with more pronounced negative values in 2023 (-US$1,324 million) and a generally lower magnitude throughout the period.

Reported Return on Assets (ROA)

Reported ROA follows the trend of net income. It increased from 12.11% in 2021 to 15.91% in 2022, then decreased sharply to 0.94% in 2023. A modest recovery occurred in 2024 (3.76%) and 2025 (3.73%), indicating a stabilization at a lower level compared to the earlier years of the period. The decline in 2023 directly correlates with the significant reduction in reported net income.

Adjusted Return on Assets (ROA)

Adjusted ROA exhibits a similar pattern to the reported ROA, but with greater volatility. It rose from 9.83% in 2021 to 14.35% in 2022, then plummeted to -0.59% in 2023, reflecting the negative adjusted net income. Subsequent years show a recovery, reaching 2.87% in 2024 and 2.81% in 2025. The negative value in 2023 suggests that, when considering adjustments, the company’s assets generated a loss during that year.

Total assets, both reported and adjusted, generally increased from 2021 to 2023. Reported total assets peaked at US$226,501 million in 2023 before decreasing to US$213,396 million in 2024 and further to US$208,160 million in 2025. Adjusted total assets followed a similar trajectory. The decrease in total assets in the later years of the period may indicate asset sales or depreciation outweighing new acquisitions.

The difference between reported and adjusted figures suggests the presence of significant non-recurring items or accounting adjustments impacting net income and, consequently, ROA. The substantial divergence in 2023, particularly the negative adjusted net income, warrants further investigation into the nature of these adjustments. The stabilization of both reported and adjusted ROA in 2024 and 2025, albeit at lower levels than in 2022, indicates a potential leveling off of performance following the volatility experienced in 2023.